IL-6 Receptor Antagonists Reduce Mortality in Critically Ill COVID-19 Patients (REMAP-CAP, RECOVERY), Convalescent Plasma Fails to Improve Mortality

Share:

Listens: 0

Last Week in Medicine

Miscellaneous

Today I am joined by Infectious Disease expert Dr. Emily Spivak to talk about the latest batch of tocilizumab trials for COVID-19 and a meta-analysis of all the convalescent plasma trials.  Check it out! Tocilizumab in Hospitalized Patients with COVID-19 (COVACTA)IL-6 Receptor Antagonists in Critically Ill Patients with COVID-19 (REMAP-CAP)RECOVERY Tocilizumab pre-printMeta-analysis of Convalescent Plasma for COVID-19Music from https://filmmusic.io"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)